THE EFFECT OF ABATACEPT ON BLOOD BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS

QR Code

THE EFFECT OF ABATACEPT ON BLOOD BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Objective: to estimate changes in the cytokine profile in patients receiving abatacept (ABC).Subjects and methods. The investigation enrolled 44 patients with rheumatoid arthritis (RA) who had been unsuccessfully treated with disease-modifying antirheumatic drugs and biological agents. A control gro...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. A. Borisova, G. V. Lukina, Ya. A. Sigidin, E. L. Luchikhina, D. E. Karateev, A. A. Novikov, E. N. Aleksandrova, M. V. Cherkasova, E. S. Aronova, S. L. Glukhova, E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2017-09-01
Series:	Научно-практическая ревматология
Subjects:	abacept rheumatoid arthritis biological therapy cytokines predictors of the effectiveness of therapy
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2409
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
by: M. A. Borisova, et al.
Published: (2017-01-01)

Infliximab in the therapy of rheumatoid arthritis
by: G. V. Lukina, et al.
Published: (2016-05-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

THE TIME COURSE OF CHANGES IN BIOMARKER LEVELS AND THE ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: O. G. Alekseeva, et al.
Published: (2015-10-01)

AN ASSOCIATION OF CYTOKINE LEVELS WITH DISEASE ACTIVITY, AUTOANTIBODY LEVELS, AND JOINT DESTRUCTIVE CHANGES IN EARLY RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2015-09-01)

Multiparameter analysis of biomarkers in the laboratory diagnosis of early rheumatoid arthritis
by: Aleksandr Aleksandrovich Novikov, et al.
Published: (2013-04-01)

CHANGES OF CYTOKINE LEVELS DURING THERAPY WITH METHOTREXATE AND ADALIMUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (REMARCA STUDY)
by: A. S. Avdeeva, et al.
Published: (2014-06-01)

USE OF MULTIPARAMETER ANALYSIS OF LABORATORY BIOMARKERS TO ASSESS RHEUMATOID ARTHRITIS ACTIVITY
by: A. A. Novikov, et al.
Published: (2016-02-01)

CYTOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ASSOCIATION WITH LUNG INJURY
by: D. V. Bestaev, et al.
Published: (2014-09-01)

Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice
by: E. S. Aronova, et al.
Published: (2020-02-01)

T-REGULATORY CELLS IN RHEUMATOID ARTHRITIS
by: E. L. Nasonov, et al.
Published: (2014-09-01)

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
by: A. A. Novikov, et al.
Published: (2011-06-01)

Infliximab in Russian clinical practice
by: G V Lukina, et al.
Published: (2012-09-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
by: E. L. Nasonov
Published: (2017-09-01)

Nimesulide in rheumatoid arthritis
by: E. L. Luchikhina
Published: (2015-06-01)

THE CLINICAL SIGNIFICANCE OF MATRIX METALLOPROTEINASES IN RHEUMATOID ARTHRITIS PATIENTS (REVIEW OF THE LITERATURE AND OUR OWN DATA)
by: Anastasiya S Avdeeva, et al.
Published: (2014-03-01)

ELABORATION AND APPLICATION OF THE DIAGNOSTIC INDEX BASED ON MULTIVARIATE ANALYSIS OF BIOMARKERS TO DETERMINE THE ACTIVITY OF RHEUMATOID ARTHRITIS
by: Aleksandr A Novikov, et al.
Published: (2014-03-01)

CYCLOSPORINE A IN RHEUMATOID ARTHRITIS: CURRENT DATA
by: Elena Lvovna Luchikhina
Published: (2009-09-01)

Evaluation of myocardial damage in different types of rheumatoid arthritisduring disease-modifying antirheumatic drug or biological therapy (with infliximab)
by: V I Mazurov, et al.
Published: (2010-12-01)

COMPARATIVE EFFICIENCY AND TOLERABILITY OF CURRENT THERAPIES FOR EARLY RHEUMATOID ARTHRITIS
by: E. V. Fedorenko, et al.
Published: (2015-04-01)

Proinflammatory cytokines and depression in rheumatoid arthritis
by: Tatyana Andreyevna Lisitsyna, et al.
Published: (2013-06-01)

Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia
by: A. S. Avdeeva, et al.
Published: (2020-05-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
by: A. S. Avdeeva, et al.
Published: (2019-03-01)

Experience with abatacept used in the treatment of patients with rheumatoid arthritis
by: V I Mazurov, et al.
Published: (2011-12-01)

ROLE OF MATRIX METALLOPROTEINASE 3 IN PREDICTING THE EFFICIENCY OF THERAPY FOR EARLY RHEUMATOID ARTHRITIS: THE REMARCA TRIAL
by: A. S. Avdeeva, et al.
Published: (2016-03-01)

Leflunomide (Arava) in early rheumatoid arthritis
by: R V Balabanova, et al.
Published: (2005-10-01)

EFFICACY OF INFLIXIMAB IN RHEUMATOID ARTHRITIS: A RELATIONSHIP TO THE TOTAL DOSE OF THE DRUG
by: E. S. Aronova, et al.
Published: (2015-10-01)

EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY
by: A. S. Avdeeva, et al.
Published: (2014-12-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY
by: E N Aleksandrova, et al.
Published: (2011-06-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
by: A. S. Avdeeva, et al.
Published: (2022-06-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

EXPERIENCE OF TREATMENT WITH ABATACEPT IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS
by: Ye. I. Alekseyeva, et al.
Published: (2011-01-01)

BIOBEHAVIORAL THERAPY OF RHEUMATOID ARTHRITIS
by: N. A. Shabanova, et al.
Published: (2013-04-01)

Relationship of cytokine level dynamics with longterm results of early rheumatoid arthritis therapy
by: V. V. Rybakova, et al.
Published: (2022-03-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
by: I. A. Guseva, et al.
Published: (2016-03-01)

Variants of intensification of immunosuppressive therapy of rheumatoid arthritis
by: E A Vasiljeva, et al.
Published: (2007-04-01)